DE60231428D1 - Medizinische aerosolzusammensetzungen mit einem funktionalisierten polyethylenglykol-hilfsstoff - Google Patents

Medizinische aerosolzusammensetzungen mit einem funktionalisierten polyethylenglykol-hilfsstoff

Info

Publication number
DE60231428D1
DE60231428D1 DE60231428T DE60231428T DE60231428D1 DE 60231428 D1 DE60231428 D1 DE 60231428D1 DE 60231428 T DE60231428 T DE 60231428T DE 60231428 T DE60231428 T DE 60231428T DE 60231428 D1 DE60231428 D1 DE 60231428D1
Authority
DE
Germany
Prior art keywords
polyethylene glycol
aerosol compositions
functionalized polyethylene
medical aerosol
glycol agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60231428T
Other languages
German (de)
English (en)
Inventor
James S Stefely
Daniel C Duan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Application granted granted Critical
Publication of DE60231428D1 publication Critical patent/DE60231428D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60231428T 2001-12-21 2002-12-20 Medizinische aerosolzusammensetzungen mit einem funktionalisierten polyethylenglykol-hilfsstoff Expired - Lifetime DE60231428D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34278701P 2001-12-21 2001-12-21
PCT/US2002/041299 WO2003059317A2 (en) 2001-12-21 2002-12-20 Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient

Publications (1)

Publication Number Publication Date
DE60231428D1 true DE60231428D1 (de) 2009-04-16

Family

ID=23343270

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60231428T Expired - Lifetime DE60231428D1 (de) 2001-12-21 2002-12-20 Medizinische aerosolzusammensetzungen mit einem funktionalisierten polyethylenglykol-hilfsstoff

Country Status (8)

Country Link
US (1) US7718162B2 (https=)
EP (1) EP1458357B1 (https=)
JP (1) JP4959919B2 (https=)
AT (1) ATE424186T1 (https=)
AU (1) AU2002367032B8 (https=)
CA (1) CA2470520A1 (https=)
DE (1) DE60231428D1 (https=)
WO (1) WO2003059317A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2470520A1 (en) 2001-12-21 2003-07-24 3M Innovative Properties Company Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient
JP2005514440A (ja) * 2001-12-21 2005-05-19 スリーエム イノベイティブ プロパティズ カンパニー アミドおよび/またはエステルを含有する、賦形剤化合物を含む、医用エアロゾル組成物
JP2005514437A (ja) * 2001-12-21 2005-05-19 スリーエム イノベイティブ プロパティズ カンパニー イオン対複合体を含む医薬用エアロゾル製剤
GB0614621D0 (en) 2006-07-24 2006-08-30 3M Innovative Properties Co Metered dose dispensers
GB0620700D0 (en) 2006-10-19 2006-11-29 3M Innovative Properties Co Metered dose valves and dispensers
DK2480197T3 (en) 2009-09-25 2016-01-25 Reddys Lab Ltd Dr Compositions containing triptanforbindelser
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
EP3020393B1 (en) 2009-12-16 2020-10-07 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
GB201118188D0 (en) 2011-10-21 2011-12-07 3M Innovative Properties Co Manufacture of medicinal aerosol canisters
GB201210580D0 (en) 2012-06-14 2012-08-01 3M Innovative Properties Co Metered dose dispensing valve
GB201221063D0 (en) 2012-11-23 2013-01-09 3M Innovative Properties Co Metered dose dispensing valve
US11981619B2 (en) 2017-07-07 2024-05-14 Basf Se Alkoxylated esteramines and salts thereof
JP7657496B2 (ja) * 2021-12-02 2025-04-07 レジェロン,インコーポレイテッド 多機能用途を有する天然賦形剤およびその調製プロセス

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1163028B (de) * 1960-03-09 1964-02-13 Hoechst Ag Verfahren zur Polymerisation von Vinylchlorid
JPS63503304A (ja) 1986-03-10 1988-12-02 ブルグハルト,クルト 医薬製剤およびその製造方法
AU601176B2 (en) 1986-03-10 1990-09-06 Kurt Burghart Benzodiazepine aerosols
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
WO1992000061A1 (en) 1990-06-29 1992-01-09 Fisons Plc Pressurised aerosol compositions
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
ATE177941T1 (de) 1992-12-09 1999-04-15 Boehringer Ingelheim Pharma Stabilisierte medizinische aerosollösungen
ES2122261T3 (es) 1993-03-17 1998-12-16 Minnesota Mining & Mfg Formulacion de aerosol que contiene un adyuvante de dispersion derivado de un ester, una amida o un mercaptoester.
ES2107203T3 (es) 1993-03-17 1997-11-16 Minnesota Mining & Mfg Una formulacion de aerosol que contiene un adyuvante de dispersion derivado de un diol-diacido.
US5492688A (en) 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
JPH09506097A (ja) 1993-12-02 1997-06-17 アボツト・ラボラトリーズ 非cfc噴射剤と共に用いるエアロゾル薬物調剤
US5508023A (en) * 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
ZA9711732B (en) * 1996-12-31 1998-12-28 Quadrant Holdings Cambridge Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US6218353B1 (en) 1997-08-27 2001-04-17 Micell Technologies, Inc. Solid particulate propellant systems and aerosol containers employing the same
US6136294C1 (en) 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
BR9914799A (pt) 1998-10-27 2001-07-10 Alcon Lab Inc Sistema conservante para composições farmacêuticas administráveis topicamente contendo um sabão de ácido graxo/aminoácido
US6258857B1 (en) 1999-02-04 2001-07-10 Kyowa Industrial Co., Ltd. Internal liquid composition contained as internal liquid in a releasing container and releasing container product
GB0016876D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Novel formulation
US7217409B2 (en) 2000-09-22 2007-05-15 Smithkline Beecham Corporation Alkanoic acid derivatives
CZ20033182A3 (cs) 2001-05-21 2004-09-15 Nektar Therapeutics Inzulínový prostředek a způsob podávání inzulínu
GB0125127D0 (en) 2001-10-19 2001-12-12 Glaxo Group Ltd Compounds
JP2005514440A (ja) 2001-12-21 2005-05-19 スリーエム イノベイティブ プロパティズ カンパニー アミドおよび/またはエステルを含有する、賦形剤化合物を含む、医用エアロゾル組成物
CA2470520A1 (en) 2001-12-21 2003-07-24 3M Innovative Properties Company Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient

Also Published As

Publication number Publication date
JP2006502086A (ja) 2006-01-19
JP4959919B2 (ja) 2012-06-27
EP1458357A2 (en) 2004-09-22
AU2002367032B2 (en) 2008-09-25
AU2002367032B8 (en) 2008-10-23
WO2003059317A2 (en) 2003-07-24
ATE424186T1 (de) 2009-03-15
AU2002367032A1 (en) 2003-07-30
US7718162B2 (en) 2010-05-18
EP1458357B1 (en) 2009-03-04
CA2470520A1 (en) 2003-07-24
WO2003059317A3 (en) 2003-11-20
US20030152521A1 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
DE60231428D1 (de) Medizinische aerosolzusammensetzungen mit einem funktionalisierten polyethylenglykol-hilfsstoff
BR9909394A (pt) Composição de aerossol, composição farmacêutica, recipiente, dispositivo de inalação, processo para preparar uma composição de aerossol, mistura de um primeiro material particulado, e, processo para administrar um medicamento particulado
EA200401006A1 (ru) Аэрозольные препараты для внутрилёгочного введения лекарств с получением системного действия
BR0214254A (pt) Pó filmogênio micronizado e composição farmacêutica, cosmética ou neutracêutica
DE69828817D1 (de) Pharmazeutische aerosolzusammensetzungen
DE69932835D1 (de) Medizinische aerosolzubereitung
DE60104399D1 (de) Pulverformulierung zur inhalation
CA2381329A1 (en) Medicaments
ES2193186T3 (es) Composiciones medicamentosas en aerosol para la utilizacion con gases propulsores sin cfc.
EP1757269A3 (en) Pulmonary formulation comprising silicon particles
BG105189A (bg) Капсула от две части за пълнене с фармацевтични препарати за прахови инхалатори
HUP0000587A1 (hu) Takrolimuszt (FK506) tartalmazó gyógyszerkészítmény
HUP9802391A2 (hu) Inhaláló berendezés szalmeterol adagolására mért dózisban
DE69428442D1 (de) Inhalationspräparate
ATE364381T1 (de) Formulierungen zur verwendung in inhalationsvorrichtungen
SI1476138T1 (sl) Formulacije s prirejenim sproščanjem vsaj ene oblike tramadola
MXPA03000442A (es) Una formulacion medicinal en aerosol.
ATE321537T1 (de) Pharmazeutische zubereitung enthaltend doxazosin
ATE265408T1 (de) Pulverisiertes mannit und verfahren zu deren herstellung
WO2003075977A3 (en) Agglomerated particles for aerosol drug delivery
DE60031504D1 (de) Fluticasonpropionat arzneizubereitung
SE9300581D0 (sv) Komposition foer nasalbehandling
ATE406152T1 (de) Medizinische aerosolzusammensetzungen mit einer eine amid- und/oder estergruppe enthaltenden exzipientenverbindung
CA2497171A1 (en) Water stabilized medicinal aerosol formulation
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition